2017
The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma
Smolka S, Chapiro J, Manzano W, Treilhard J, Reiner E, Deng Y, Zhao Y, Hamm B, Duncan JS, Gebauer B, Lin M, Geschwind JF. The impact of antiangiogenic therapy combined with Transarterial Chemoembolization on enhancement based quantitative tumor response assessment in patients with hepatocellular carcinoma. Clinical Imaging 2017, 46: 1-7. PMID: 28668723, PMCID: PMC5720941, DOI: 10.1016/j.clinimag.2017.05.007.Peer-Reviewed Original ResearchConceptsEarly response assessmentTransarterial chemoembolizationImaging-based criteriaResponse assessmentHepatocellular carcinomaTumor response assessmentAnti-angiogenic therapyQuantitative European AssociationTherapy armOverall survivalLiver criteriaAntiangiogenic therapyTreatment groupsPatientsSimilar associationEuropean AssociationBevacizumabChemoembolizationCarcinomaTherapyAssociationAssessmentFollowCriteriaBaseline
2015
Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions
Duran R, Chapiro J, Schernthaner RE, Geschwind JF. Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions. British Journal Of Radiology 2015, 88: 20140564. PMID: 25978585, PMCID: PMC4651391, DOI: 10.1259/bjr.20140564.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntineoplastic AgentsCarcinoma, HepatocellularCatheter AblationChemoembolization, TherapeuticCombined Modality TherapyDiffusion of InnovationEmbolization, TherapeuticFemaleForecastingHumansInfusions, Intra-ArterialLiver NeoplasmsMaleMicrospheresNiacinamidePatient SelectionPhenylurea CompoundsRadiopharmaceuticalsSorafenibYttrium RadioisotopesConceptsIntra-arterial therapyHepatocellular carcinomaSecondary liver malignanciesManagement of patientsHealthy liver tissueLocoregional therapyLiver malignanciesClinical rationaleHigh doseInterventional oncologySystematic reviewAnticancer treatmentLiver tissueInvasive natureClinical achievementsChemoresistant cancersTherapyMedical communityPatientsCarcinomaTreatmentPivotal roleMalignancySorafenibCancer